“…extent, in several EU countries (Rani et al, 2008;Kalverdijk et al, 2008). With the possible exception of psychostimulants, this increase in prescription rates pertains mostly to the off-label use of second-generation antipsychotics (SGAs) or selective serotonin reuptake inhibitors (SSRIs) (Koelch et al, 2009). Country-specific practices may underlie these trends: in Canada, prescriptions of antipsychotics to youngsters (frequently off-label) are disproportionately higher among general practitioners than among psychiatrists (Murphy et al, 2013), whereas in Germany hospital-based specialists prescribe significantly more antidepressants offlabel compared to general practitioners (Dörks et al, 2013).…”